JPMorgan added Akero Therapeutics to the firm’s Analyst Focus List and placed a “Positive Catalyst Watch” on the shares. This follows the firm increased its price target to reflect higher conviction in the SYMMETRY readout.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AKRO: